阿斯利康乳腺癌药物Enhertu预防复发效果优于竞品 有望治愈早期患者

GateNews

金十数据10月20日讯,阿斯利康和日本药企第一三共的抗癌药物Enhertu为早期乳腺癌患者带来了更好的治疗效果。在上周末于柏林举行的欧洲肿瘤学会会议上公布的两项关键试验中,Enhertu在预防疾病复发方面的表现优于罗氏公司的Kadcyla,且在手术前使用时效果更佳。

Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments carry high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to Disclaimer.
Commento
0/400
Nessun commento